Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Cambridge Material Testing Solutions

19 Jun 2018 07:00

RNS Number : 7039R
Frontier IP Group plc
19 June 2018
 

RNS REACH / RNS

AIM: FIPP

19th June 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - New Portfolio Company, Cambridge Material Testing Solutions

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces it has taken a 24 per cent stake in Cambridge Material Testing Solutions ("the Company"), a business established to support the work of Dr James Dean, an expert in the mechanics and deformation of materials.

 

The Company is developing software and hardware to measure material characteristics in critical metal components more swiftly, cost effectively, and accurately than other systems. Among other potential benefits is mobile and remote testing on site, and the ability to assess complex components and joints.

 

The technology has a very wide range of applications in several sectors, including in the aerospace, nuclear, and oil and gas industries where material degradation and component life assessment of high value assets is critically important.

 

Currently, the hardware used to measure material characteristics forces a hard tip into a metal surface to create an indent. The material response characteristics are measured, allowing simple measurements of hardness and stiffness to be made. Existing indentation test equipment is bulky and laboratory based.

 

Cambridge Material Testing Solutions is addressing the materials testing challenges facing industry by focusing on two development areas:

 

o a suite of software tools, called SEMPID. This can process data generated by existing indentation test equipment and swiftly convert it into information easily understood by engineers to assess the strength and remaining working life of metal components;

 

o customised indentation test equipment. The new systems will be desktop-based, mobile, or fixed on site to assess critical components while in service.

 

Dr James Dean received his PhD from the Department of Materials Science at the University of Cambridge. He has worked for Frazer Nash Consultancy, a leading systems and engineering technology company, on a number of projects, mainly in the nuclear and aerospace industries. He then joined Double Precision Consultancy, a specialist in tackling complex engineering challenges.

 

 

More details about the technology are below.

 

Frontier IP Chief Executive Officer Neil Crabb said: "Frontier IP is delighted to be working with Dr. James Dean and his team to help accelerate the commercialisation of this exciting technology. We believe Cambridge Material Testing Solutions could prove invaluable to companies in critical sectors which need to ensure the materials they use are safe and robust."

 

Cambridge Material Testing Solutions' Chief Technology Officer, Dr. James Dean said: "Our partnership with Frontier IP is further confirmation of our proposition's value. With Frontier IP's expertise in the commercialisation of advanced technologies and its ready access to the sectors we intend to penetrate, where the accurate and non-destructive characterisation of material properties is crucial to the safe operation of high value assets."

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

 

About the Cambridge Materials Testing Solutions technology:

The Company is initially developing a suite of user-friendly software packages that allow rapid and accurate evaluation of the parameters that characterise mechanical properties (such as yield stress and work hardening rate) from instrumented indentation tests. These non-destructive tests are quick and easy to carry out.

 

Another major attraction is that such experiments require only small samples of simple shape (such as plates of mm dimensions), while mapping of local properties over the surface of larger samples is also possible.

 

The suite of software packages, called SEMPID (Software for the Extraction of Material Properties from Indentation Data), are application specific tools for converting indentation data into mechanical material parameters and stress-strain curves.

 

An application for the calculation of stress-strain curves (plasticity parameters) is already available in beta version. This application can process data generated during an indentation test (load-displacement curves or residual indent shapes) and swiftly convert it into stress-strain data that can subsequently be used to assess the strength and remaining working life of metal components.

 

Their software solutions can significantly reduce materials testing turnaround times and materials testing costs.

 

In addition, and as part of their proposed portfolio of materials testing solutions, the Company is developing a customised suite of indentation test equipment including a bespoke desktop-based indenter, and a portable indenter for remote testing of in-service and on-site components.

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASFESUAFASELM
Date   Source Headline
18th Feb 20257:00 amRNS-RTopps Tiles launches Alusid’s Mas floor tiles
31st Dec 20241:30 pmRNSTotal Voting Rights
30th Dec 20249:56 amRNSHolding(s) in Company
20th Dec 20247:00 amRNSGrant of Options
19th Dec 20244:14 pmRNSResult of AGM
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20241:36 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSPosting of Circular & Annual Report, & AGM Notice
26th Nov 20247:00 amRNSResult of Retail Offer
22nd Nov 20241:31 pmRNSResult of Placing and Subscription
22nd Nov 20248:12 amRNSRetail Offer by PrimaryBid
22nd Nov 20247:01 amRNSProposed Placing and Subscription
22nd Nov 20247:00 amRNSFinal results for the year ended 30 June 2024
29th Oct 20244:45 pmRNSHolding(s) in Company
11th Sep 202412:10 pmRNSHolding(s) in Company
7th Aug 20243:52 pmRNSHolding(s) in Company
6th Aug 20243:47 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSPortfolio – Cambridge Raman Imaging loan facility
19th Jun 20247:00 amRNSHolding(s) in Company
24th May 20247:00 amRNSTopps Group’s arm launches Alusid floor tile range
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.